Several pivotal trials, including the METROS trial,13 the PROFILE 1001 study14 and the OO 12-01 study,15 have demonstrated that crizotinib elicits a durable response and extends the progression-free survival (PFS) of patients with ROS1-rearranged advanced NSCLC, establishing ROS1 as a valid therapeutic target in ROS1-rearranged lung cancers. This evidence concerns the gene ROS1 and lung carcinoma.